Basic Information
| LncRNA/CircRNA Name | LINC00239 |
| Synonyms | NR_026774.1 |
| Region | NA |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | acute myeloid leukemia |
| ICD-0-3 | NA |
| Methods | qPCR |
| Sample | AML cell lines(KG-1, HL-60) |
| Expression Pattern | up-regulated |
| Function Description | In the present study, we investigated the effects of lncRNA linc00239 (NR_026774.1), which is 662 nucleotides (nt) in length and was found to be upregulated in AML patients, on malignant behaviours and chemosensitivity in AML cells, including KG-1 and HL-60. |
| Pubmed ID | 30720129 |
| Year | 2019 |
| Title | Long non-coding RNA linc00239 promotes malignant behaviors and chemoresistance against doxorubicin partially via activation of the PI3K/Akt/mTOR pathway in acute myeloid leukaemia cells. |
External Links
| Links for LINC00239 | GenBank HGNC NONCODE |
| Links for acute myeloid leukemia | OMIM COSMIC |